 OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a company developing late-stage intratumoral DNAbased cancer immunotherapies, today announced that Kellie Malloy Foerter, previously Chief Clinical Development Officer, has been appointed Chief Operating Officer, effective immediately. With this promotion, Kellies leadership responsiblities will expand to now include the Companys finance, engineering and HR functions, while continuing her leadership of OncoSecs clinical operations, including its two ongoing KEYNOTE clinical trials with lead product candidate, TAVOTM interleukin 12 or IL-12 plasmid. 